Investigational Drug Information for ASP1517
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for ASP1517?
ASP1517 is an investigational drug.
There have been 24 clinical trials for ASP1517.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 3rd 2013.
The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Inc, and Astellas Pharma Europe B.V.
There are forty-four US patents protecting this investigational drug and three hundred and eighty-seven international patents.
Summary for ASP1517
| US Patents | 44 |
| International Patents | 387 |
| US Patent Applications | 196 |
| WIPO Patent Applications | 119 |
| Japanese Patent Applications | 43 |
| Clinical Trial Progress | Phase 3 (2013-09-03) |
| Vendors | 85 |
Recent Clinical Trials for ASP1517
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | FibroGen | Phase 1 |
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | Astellas Pharma Global Development, Inc. | Phase 1 |
| Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden | Astellas Pharma Inc | Phase 3 |
Clinical Trial Summary for ASP1517
Top disease conditions for ASP1517
Top clinical trial sponsors for ASP1517
US Patents for ASP1517
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP1517 | See Plans and Pricing | Nitrogen-containing heteroaryl compounds and methods of use thereof | FibroGen, Inc. (San Francisco, CA) | See Plans and Pricing |
| ASP1517 | See Plans and Pricing | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | See Plans and Pricing |
| ASP1517 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| ASP1517 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| ASP1517 | See Plans and Pricing | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | See Plans and Pricing |
| ASP1517 | See Plans and Pricing | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP1517
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP1517 | Austria | AT496033 | 2023-06-06 | See Plans and Pricing |
| ASP1517 | Australia | AU2004245552 | 2023-06-06 | See Plans and Pricing |
| ASP1517 | Brazil | BRPI0411055 | 2023-06-06 | See Plans and Pricing |
| ASP1517 | Canada | CA2528232 | 2023-06-06 | See Plans and Pricing |
| ASP1517 | China | CN102718708 | 2023-06-06 | See Plans and Pricing |
| ASP1517 | China | CN102977015 | 2023-06-06 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
